225 related articles for article (PubMed ID: 22188897)
1. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions.
Elstner M; Müller SK; Leidolt L; Laub C; Krieg L; Schlaudraff F; Liss B; Morris C; Turnbull DM; Masliah E; Prokisch H; Klopstock T; Bender A
Mol Brain; 2011 Dec; 4():43. PubMed ID: 22188897
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
3. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?
Herrero MT; Hirsch EC; Kastner A; Ruberg M; Luquin MR; Laguna J; Javoy-Agid F; Obeso JA; Agid Y
Neuroscience; 1993 Sep; 56(2):499-511. PubMed ID: 8247275
[TBL] [Abstract][Full Text] [Related]
4. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y
J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900
[TBL] [Abstract][Full Text] [Related]
5. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
6. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy.
Matsuura K; Maeda M; Yata K; Ichiba Y; Yamaguchi T; Kanamaru K; Tomimoto H
Eur Neurol; 2013; 70(1-2):70-7. PubMed ID: 23796701
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease.
Bury AG; Pyle A; Elson JL; Greaves L; Morris CM; Hudson G; Pienaar IS
Ann Neurol; 2017 Dec; 82(6):1016-1021. PubMed ID: 29149768
[TBL] [Abstract][Full Text] [Related]
8. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
[TBL] [Abstract][Full Text] [Related]
9. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease.
Sanders LH; McCoy J; Hu X; Mastroberardino PG; Dickinson BC; Chang CJ; Chu CT; Van Houten B; Greenamyre JT
Neurobiol Dis; 2014 Oct; 70():214-23. PubMed ID: 24981012
[TBL] [Abstract][Full Text] [Related]
11. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
12. Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
Krainc T; Monje MHG; Kinsinger M; Bustos BI; Lubbe SJ
Mov Disord; 2023 Feb; 38(2):185-195. PubMed ID: 36350228
[TBL] [Abstract][Full Text] [Related]
13. Increased mitochondrial DNA deletions in substantia nigra dopamine neurons of the aged rat.
Parkinson GM; Dayas CV; Smith DW
Curr Aging Sci; 2014; 7(3):155-60. PubMed ID: 25612740
[TBL] [Abstract][Full Text] [Related]
14. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders.
Gu G; Reyes PE; Golden GT; Woltjer RL; Hulette C; Montine TJ; Zhang J
J Neuropathol Exp Neurol; 2002 Jul; 61(7):634-9. PubMed ID: 12125742
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial Dysfunction Combined with High Calcium Load Leads to Impaired Antioxidant Defense Underlying the Selective Loss of Nigral Dopaminergic Neurons.
Ricke KM; Paß T; Kimoloi S; Fährmann K; Jüngst C; Schauss A; Baris OR; Aradjanski M; Trifunovic A; Eriksson Faelker TM; Bergami M; Wiesner RJ
J Neurosci; 2020 Feb; 40(9):1975-1986. PubMed ID: 32005765
[TBL] [Abstract][Full Text] [Related]
17. Neuromelanin accumulation with age in catecholaminergic neurons from Macaca fascicularis brainstem.
Herrero MT; Hirsch EC; Kastner A; Luquin MR; Javoy-Agid F; Gonzalo LM; Obeso JA; Agid Y
Dev Neurosci; 1993; 15(1):37-48. PubMed ID: 7505739
[TBL] [Abstract][Full Text] [Related]
18. Neuromelanin and Parkinson's disease.
Marsden CD
J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
[TBL] [Abstract][Full Text] [Related]
19. Changes in cytoplasmic and extracellular neuromelanin in human substantia nigra with normal aging.
Korzhevskii DE; Kirik OV; Guselnikova VV; Tsyba DL; Fedorova EA; Grigorev IP
Eur J Histochem; 2021 Sep; 65(s1):. PubMed ID: 34468106
[TBL] [Abstract][Full Text] [Related]
20. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
Hirsch E; Graybiel AM; Agid YA
Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
